Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Pharmacokinetics of CKD-379 in Healthy Volunteers
NCT06204107Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-379 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Time t and Maximum Plasma Concentration. Started Nov 2023; status: completed.
02
Drugs
CKD-379
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06204107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06204107.